-S #14 Dr
Once your documentation is sorted, there's still the journey itself to prepare for
In this manuscript we report: 1) for the first time our findings on the (3 + 2) methodology, 2) expanded substrate scope for the (4 + 3) annulation, 3) the identification of one of these compounds, JWU-A021, as a potent GLP-1 secretagogue, and 4) experimental evidence indicating that JWU-A021 likely operates in the intestinal L-cells by elevating the intracellular [Ca 2+ ] by means of activating the Transient Receptor Potential Ankyrin 1 channel (TRPA1) 4
The stationary phase consists of a Raptor 50 mm 2.1 mm, 2.7 m, C18 column (Restek, Bellefonte, PA) for the separation of the analytes and a Raptor C18 guard column (Restek, Bellefonte, PA)
Common GLP-1s available in Canada (as of 2025) include: *T irzepatide is dual-acting (GIP + GLP-1), which sets it apart pharmacologically but places it in the same broader category of incretin-based therapies